Fang HW#, Tseng PL#(co-first), Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy. Virol J. 2024 Apr 3;21(1):79. (SCI)
Sonneveld MJ, Chiu SM(Co first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Janssen HL, Berg T, Zoulim F, ....., Chen CH*, Maasoumy B*, CREATE Study Group. Hepatitis B Virus DNA and Hepatitis B e Antigen Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and Hepatitis B Antigen Loss in Hepatitis B e Antigen-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology. 2024 Jan; 166(1):168-177.e8. (SCI)
Fang HW, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Post-treatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment. Dig Liver Dis. 2023 Sep;55(9):1223-1229. (SCI)
Chen CH*, Peng CY, Hu TH, Wang JH, Hung CH, Lu SN. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023 Aug;58(3):334-345. (SCI)
Sonneveld MJ, Chiu SM(co-first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Berg T, Zoulim F, Hoon Ahn S, Dalekos GN, .......,Chen CH*, Maasoumy B*. CREATE study group Affiliations expnd. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study. JHEP Rep. 2023 Aug ;5(8):100790. (SCI)
Chen CH*, Jeng WJ(co-first), Hu TH, Liu YC, Wang JH, Hung CH, Lu SN, Chien RN. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Dig Liver Dis. 2023 Jun;55(6):771-777. (SCI)
Wang HW, Chen CY, Lai HC, Hu TH, Su WP, Lu SN, Hung CH, Chuang PH, Wang JH, Chen CH*, Peng CY*. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy. Am J Cancer Res. 2023 Feb 15;13(2):526-537. (SCI)
Chiu SM, Chang KC, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Dig Dis Sci. 2023 Feb;68(2):665-675. (SCI)
Tseng TN(co-first), Jeng WJ(co-first), Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. J Antimicrob Chemother. 2023 Feb 1;78(2):436-439. (SCI)
Liu YC, Jeng WJ, Chen CH*. Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1890-1891. (SCI)
Letter to the Editor
Chen CH*, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY*. A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy. Cancers (Basel). 2022 Oct 16;14(20):5063. (SCI)
Tseng TN, Chen CH*. Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022 Sep;56(5):916-917. (SCI)
Fang HW, Yen YH, Hung CH, Wang JH, Hu TH, Lu SN, Chen CH*. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. Dig Dis Sci. 2022 Jul;67(7):3402-3411. (SCI)
Chen CH*, Peng CY, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN. Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients. J Infect Dis. 2022 Jun 1;225(11):1974-1981. (SCI)
Tseng TN, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. Viruses. 2022 May 30;14(6):1189. (SCI)
Jeng WJ*, Chen CH*, Wang YW, Pan MH, Lin CW, Lin CY, Yang HI*. The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays. Virol J . 2022 Mar 31;19(1):59. (SCI)
Sonneveld MJ*, Chiu SM(co-first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bommel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Honer Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH*, Maasoumy B; Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. CREATE study group. J Hepatol. 2022 May;76(5):1042-1050. (SC
Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, Ng HY, Chen CH*. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk Lymphoma. 2021 Dec;62(12):2899-2906. (SCI)
Huang PY, Wang JH, Hung CH, Lu SN, Hu TH*, Chen CH*. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat. 2021 Aug;28(8):1141-1149. (SCI)
Peng CY*, Chen CH*. On-treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B. Liver Int. 2021 Jul;41(7):1700-1701. (SCI)
Kuo YH , Wang JH, Hung CH, Lu SN, Hu TH*,Chen CH*.Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int. 2021 Apr;15(2):301-309. (SCI)
Chen CH*, Chen CY, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY*. Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. Am J Cancer Res. 2020 Nov 1;10(11):3882-3895.
Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, Chen CH*. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir therapy. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2989-2997.e3. (SCI)
Tseng TN, Hu TH, Wang JH, Kuo YH, Hung CH, Lu SN, Jeng WJ*, Chen CH*. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2803-2812.e2. (SCI)
Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY*, Chen CH*. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020 Jul;14(4):513-520. (SCI)
Hsieh YC, Lin CL, Hung CH, Chen CH, Tung SY*, Lin CY, Hu TH, Lu SN, Chien RN, Sheen IS. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. J Viral Hepat. 2020 May;27(5):505-513. (SCI)
Chen CH*, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY*. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int. 2020 May;14(3):317-325. (SCI)
Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH*, Peng CY*. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers (Basel). 2020 May 7;12(5):1177. (SCI)
Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH*. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs. 2020 Feb;38(1):202-210. (SCI)
Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One. 2019 Oct 4;14(10):e0222221. (SCI)
Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH*. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci. 2019 Sep;64(9):2563-2569. (SCI)
Chen CH, Chen CH(co-first), Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH*, Sheen IS*. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir?±?ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep. 2019 May 8;9(1):7086. doi: 10.1038/s41598-019-43554-3. (SCI)�
Chen CH*, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, Lin CH, Peng CY*. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. J Infect Dis. 2019 Apr 19;219(10):1624-1633. (SCI)
Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH*, Peng CY*. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol. 2019 Feb;34(2):442-449. (SCI)
Chen CH*. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply. Aliment Pharmacol Ther. 2019 Apr;49(8):1106-1107. (SCI)
Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, Chen CH*. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2019 Jan;49(2):218-228. (SCI)
Chiang HH, Lee CM, Hu TH, Hung CH, Wang JH, Lu SN, Lai HC, Su WP, Lin CH, Peng CY*, Chen CH*. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int. 2018 Nov;38(11):1997-2005. (SCI)
Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J Gastroenterol Hepatol. 2018 Oct;33(10):1766-1772. (SCI)
Chen CH*, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018 Sep;24(9):997-1003. (SCI)
Chen CH, Hsu YC, Lu SN, Hung CH, Wang JH, Lee CM, Hu TH*. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat. 2018 May;25(5):590-597. (SCI)
Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY*. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget. 2017 Sep 28;8(54):92431-92441. doi: 10.18632/oncotarget.21369. (SCI)
Wu IT, Hu TH, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH*. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017 Jul;23(7):464-469. (SCI)
Hung CH, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH*. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat. 2017 Jul;24(7):599-607. (SCI)
Chen CH*. Editorial: hepatitis B reactivation in patients with chronic hepatitis C treated with direct-acting antivirals - incidence, severity of hepatitis and lessons to learn. Aliment Pharmacol Ther. 2017 May;45(10):1373-1374. doi: 10.1111/apt.14051. (SCI)
Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH*. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg???200?IU/mL. Sci Rep. 2017 May 12;7(1):1839. (SCI)�
Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH*, Chen CH*. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and -experienced chronic hepatitis B patients. J Gastroenterol Hepatol. 2016 Jul;31(7):1307-14. (SCI)
Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM*. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2015 Nov;13(11):1984-1992. (SCI)
Pei SN, Chen CH*. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma. 2015 Jun;56(6):1611-8. (SCI)
Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH*. Tenofovir versus Entecavir in Treatment of Chronic Hepatitis B Virus with Severe Acute Exacerbation. Antimicrob Agents Chemother. 2015 Jun;59(6):3168-73. (SCI)
Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Hsu MC, Chen CH*. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol. 2015 May;30(5):918-24. (SCI)
Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM*. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014 Sep;61(3):515-22. (SCI)
Kuo LF, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Chen CH*. High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years. Dig Dis Sci. 2014 Oct;59(10):2580-7. (SCI)
Chen CH, Hu TH, Hung CH, Wang JH, Lu SN, Lee CM*. Antiviral effect of entecavir in nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat. 2014 Aug;21(8):e55-64. (SCI)
Chen CH*, Lu SN, Lee CM, Hung CH, Wang JH, Hu TH. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion. Hepatol Int. 2014 July; 8(3): 365-374. (SCI)
Chen CH, Lin CL(co-first), Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN*, Lee CM*. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014 Jun;60(6):1127-34. (SCI)
Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH*. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol. 2014 Jun 28;20(24):7686-7695. (SCI)
Tsai MC, Yu HC(co-first), Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH*, Hu TH*. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014 Mar;29(3):568-75. (SCI)
Tsai MC, Chen CH*, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH*. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014 Feb;20(2):O90-O100. (SCI)
Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH*. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013 Sep;68(9):2154-63. (SCI)
Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, Changchien CS, Lee CM*. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naive and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013 July; 7(3):832-843. (SCI)
Yang SC, Lu SN, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH*. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatol Int. 2013 June. 7(2):489-499. (SCI)
Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN*. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int. 2013 June;7(2):477-488. (SCI)
Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH*. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012 Jul;91(7):1007-12. (SCI)
Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM*. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Antivir Ther. 2012;17(4):701-9. (SCI)
Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN*. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. (SCI)
Chen CH, Chiu YC, Chou YP, Kuo CM, Wu KL, Chuah SK*. Cronkhite-Canada Syndrome: Report of a Case. Gastroenterol J Taiwan. 2011 Mar;28(1):57-61.
Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM*. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. Liver Int. 2011 Feb;31(2):206-14. (SCI)
Chen CH, Lee CM*, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol. 2010 Apr;52(4):478-85.(SCI)
Chen CH, Changchien CS, Lee CM*, Tung WC, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer. 2009 Aug 1;125(3):621-9. (SCI)
Lin MT, Kuo YH, Chuah SK, Chiu YC, Huang CC, Tai WC, Chen CH*, Lee CM. Mantle cell lymphoma with diffuse gastrointestinal tract involvement: A case report. J Internal Medicine of Taiwan 2009 Dec;20(6):555-560.
Chen CH, Changchien CS, Lee CM*, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infect Dis. 2008 Dec 1;198(11):1634-42. (SCI)
